Medifast (NYSE:MED – Free Report) had its price objective lowered by DA Davidson from $17.00 to $16.50 in a research report sent to investors on Wednesday morning,Benzinga reports. DA Davidson currently has a neutral rating on the specialty retailer’s stock.
Medifast Stock Up 2.7 %
MED stock opened at $14.71 on Wednesday. The business’s fifty day simple moving average is $16.25 and its two-hundred day simple moving average is $17.97. Medifast has a twelve month low of $13.57 and a twelve month high of $42.68. The firm has a market cap of $160.96 million, a price-to-earnings ratio of 81.74 and a beta of 1.14.
Medifast (NYSE:MED – Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. The company had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. Medifast had a net margin of 0.35% and a return on equity of 10.64%. Research analysts expect that Medifast will post 0.51 EPS for the current year.
Institutional Inflows and Outflows
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
- Five stocks we like better than Medifast
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- The Basics of Support and Resistance
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.